Mexifin, 50 mg/ml 2 ml 10 pcs

Mexifin belongs to the group of compounds of 3-oxypyridine and succinic acid and has antioxidant, antihypoxic, membrane stabilizing, nootropic, stress-protective, anticonvulsant and anxiolytic effects.

. Mexifin acts as an inhibitor of free radicals, inhibits lipid peroxidation, increases the activity of antioxidant enzyme system, restores the structure and function of membranes disturbed in various pathologies, modulates the effect on membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholindinesterase), ion channels, receptor complexes, including benzodiazepine, GABA, acetylcholine; improves transport of neurotransmitters, synaptic transmission and interconnection of brain structures.

Enhances content of dopamine in the brain. The mechanism of action of mexiphine is due to its ability to enhance compensatory activation of aerobic glycolysis. It decreases the degree of inhibition of oxidative processes in the Krebs cycle in hypoxia by increasing the content of ATP and creatine phosphate, helps to maintain the structural and functional organization of biomembranes.

Mexifin improves cerebral metabolism and blood supply of the brain, corrects disorders in the regulatory and microcirculatory systems by inhibiting constriction of arterioles and precapillaries; Improves blood rheology by reducing platelet aggregation, stabilizing membrane structures of blood cells (erythrocytes and platelets), prevents hemolysis; improves immune system activity.

Mexifin has anti-atherogenic effect, causing regression of atherosclerotic changes in the arteries, reducing levels of cholesterol and low-density lipoproteins and restoring lipid homeostasis.

Mexifin improves performance and resistance to various extreme damaging factors of oxygen-dependent pathological conditions (shock, stress, hypoxia and ischemia, cerebral blood flow disorders, physical and mental overload), intoxication with alcohol and antipsychotic drugs (neuroleptics).

Indications

Acute and chronic cerebrovascular accidents, including ischemic stroke and its consequences;
dyscirculatory encephalopathy, vegetative-vascular dystonia;
psychosomatic diseases;
neurotic and neurosis-like disorders with the manifestation of anxiety, fear, emotional stress;
memory and attention disorders, impaired mental performance;
mental and neurological diseases in old age, cerebral atherosclerosis;
relief of alcohol withdrawal syndrome, accompanied by neurosis-like and vegetative-vascular disorders;
acute intoxication with neuroleptics;
acute purulent-inflammatory processes of the abdominal cavity: acute necrotizing pancreatitis, peritonitis (as part of complex therapy).

Pharmacological effect

Mexifin belongs to the group of compounds of 3-hydroxypyridine and succinic acid and has antioxidant, antihypoxic, membrane-stabilizing, nootropic, stress-protective, anticonvulsant and anxiolytic effects.

Meksifin acts as an inhibitor of free radicals, inhibits the processes of lipid peroxidation, increases the activity of the antioxidant enzyme system, restores the structure and function of membranes impaired in various pathologies, has a modulating effect on membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholine diesterase), ion channels, receptor complexes, including benzodiazepine, GABA, acetylcholine; improves neurotransmitter transport, synaptic transmission and interconnection of brain structures.

Increases dopamine levels in the brain. The mechanism of action of mexifin is due to its ability to enhance the compensatory activation of aerobic glycolysis. It reduces the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions, increasing the content of ATP and creatine phosphate; contributes to the preservation of the structural and functional organization of biomembranes.

Mexifin improves cerebral metabolism and blood supply to the brain, corrects disturbances in the regulatory and microcirculatory systems, suppressing constriction of arterioles and precapillaries; improves the rheological properties of blood, reducing platelet aggregation, stabilizing the membrane structures of blood cells (erythrocytes and platelets), preventing hemolysis; improves the functioning of the immune system.

Meksifin has an antiatherogenic effect, causing regression of atherosclerotic changes in the arteries, reducing cholesterol and low-density lipoprotein levels, restoring lipid homeostasis.

Meksifin increases the performance and resistance of the body to the effects of various extreme damaging factors in oxygen-dependent pathological conditions (shock, stress, hypoxia and ischemia, cerebrovascular accidents, physical and mental overload), intoxication with alcohol and antipsychotics (neuroleptics).

Active ingredient

Ethylmethylhydroxypyridine succinate

Composition

Active ingredient:

ethylmethylhydroxypyridine succinate – 50 mg;

Excipient – water for injection

Pregnancy

Contraindicated

Contraindications

Hypersensitivity to hydroxymethylethylpyridine succinate and/or pyridoxine, acute impairment of liver and kidney function, pregnancy, breastfeeding.

Side Effects

Nausea, dry mouth, allergic reactions.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

FSUE Pharmzaschita NPC, Russia